ZNZiHan Niu

ZiHan Niu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


ZiHan Niu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Jie Liu

    Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

    2 shared publications
  • Qingli Zhu

    Department of Ultrasound, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    2 shared publications
  • Dingding Zhang

    Center for Prevention and Early Intervention, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    1 shared publication
  • HongZhong Jin

    Department of Dermatology Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

    1 shared publication
  • YueHua Liu

    Department of Dermatology Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

    1 shared publication
  • Yukun Wang

    Department of Dermatology & Venereology, West China Hospital Sichuan University Chengdu China

    1 shared publication

Latest Publications

  • Open Access

    Improve the dupilumab therapy evaluation with dermoscopy and high‐frequency ultrasound in moderate‐to‐severe atopic dermatitis

    by Zhaorui Liu, Zihan Niu, Dingding Zhang, Jie Liu, Qingli Zhu

    Background: Atopic dermatitis (AD) is a chronic inflammatory disease. Monoclonal antibody dupilumab was approved to treat moderate‐to‐severe AD in recent years. An objective assessment of treatment response by skin imaging modality is adjuvant for clinical evaluations. This study aimed to explore the value of dermoscopy and high‐frequency ultrasound (HFUS) imaging characteristics in treatment evaluation for moderate‐to‐severe AD patients treated with dupilumab.Methods: Moderate‐to‐severe AD patients refractory to conventional therapy were enrolled in the study. All patients went through at least a 16‐week standardized treatment of dupilumab. Clinical scores (eczema area scoring index [EASI], SCOARD, numerical rating scale of pruritus, dermatology life quality index), dermoscopy, and HFUS examinations were conducted at 0, 2, 4, 8, 12, and 16 weeks of treatment. Erythema, scales, erosion, and pigmentation under dermoscopy were scored, and subepidermal low‐echogenic band (SLEB) thickness under HFUS was measured as quantitative indexes. Descriptive analysis and mixed effect linear regression models were used for statistical analysis.Results: Sixteen patients were enrolled in the study and their average age was 45.63 ± 18.18 years. All clinical scores decreased with significant difference after 16‐week treatment compared with baseline. All patients achieved EASI 50 (EASI score decreased by 50% or more), and 9/16 patients reached EASI 75 after 16‐week treatment. Dermoscopy evaluation of erythema, scales and erosion scores were decreased, and the sign of pigmentation score was increased after treatment. For HFUS, the mean SLEB value was 0.51 ± 0.29 mm and decreased to 0.27 ± 0.15 mm after 16‐week treatment (p < 0.01). SLEB value decreased linearly with treatment time and correlated with clinical scores. However, SLEB values of two patients were 0.57 and 0.68 mm at week 16, respectively, which were higher than the average, and one of the patients showed EASI 75.Conclusion: Dermoscopy and HFUS were able to reveal deeper inflammation response than clinical scores in AD and can be an effective method to evaluate and monitor clinical improvement during dupilumab treatment for AD patients. The preliminary value of imaging methods for predicting the treatment endpoint of dupilumab remains to be verified.


  • The value of high‐frequency ultrasonography in the differential diagnosis of early mycosis fungoides and inflammatory skin diseases: A case‐control study

    by ZiHan Niu, YuKun Wang, QingLi Zhu, Jie Liu, YueHua Liu, HongZhong Jin

    Background: The clinical manifestations of early mycosis fungoides (eMF) are non‐specific and similar to inflammatory skin diseases. High‐frequency ultrasonography (HF‐US) can show small structure of skin lesions and is helpful to provide information objectively.Materials and Methods: A case‐control study was designed in 62 patients with multiple erythemas and scales, including 18 eMF and 44 age‐matched patients with eczema (EC) or psoriasis vulgaris (PsV). The most significant lesions were collected by 50 MHz HF‐US. The assessment of ultrasound included epidermal morphology and thickness, infiltration depth, subepidermal low echogenic band (SLEB) boundary and thickness, internal echo, and number of linear acoustic shadows (LAS) behind the epidermis. The ultrasonic characteristics of eMF, EC, and PsV lesions were analyzed.Results: Epidermal thickness (P < .001, sensitivity 88.9%, specificity 75.0%) and SLEB thickness (P = 0.006, sensitivity 55.6%, specificity 90.9%) were useful for differential diagnosis of eMF and PsV/EC. When eMF was diagnosed by epidermal thickness < 0.2375 mm, the AUC was 0.845, which had the highest diagnostic efficacy among all ultrasound signs. In addition, compared with eMF and EC, the LAS number of PsV lesions was the highest and statistically significant.Conclusion: The results showed that HF‐US could provide some extra information in identification of eMF, EC, and PsV and has potential clinical value.